Snowball logo
logo
4561

G2GBIO Inc.

456160 • KQ
₩45,200.00-₩4,500.00  (9.05%)
Estimate
Beta
0.187
Growth
FCF, YoY
-28.37%
About the company
Ticker
456160
ISIN
Country
South Korea
Sector (GICS)
Healthcare
G2GBIO Inc., a clinical-stage biotech company, provides pharmaceutical products. The company's pipeline products include GB-5001, GB-5001A, and GB-5112 for the treatment of Alzheimer's disease; GB-6002, an opioid drug that is used for post-operative pain treatment; GB-7001 for type-2 diabetes treatments; GB-5313 for the treatment of Osteoarthritis; GB-7101 and GB-7103 for the treatment of prostate cancer; GB-6201 and GB-6203 for androgenetic alopecia treatments; and GH-001 for the treatment of Hepatitis B. It also develops GB-2001 for animal castration; and GB-2006, an animal postoperative pain relief drug, which is in clinical trial stage. The company was founded in 2017 and is headquartered in Cheongju-si, South Korea.

Frequently asked questions

What sector does G2GBIO Inc. (456160) operate in?

G2GBIO Inc. belongs to the Healthcare sector and operates in the Biotechnology industry.

What is G2GBIO Inc. (456160) current stock price?

As of the latest data, G2GBIO Inc. stock price is ₩45,200, with a previous close of ₩49,700. G2GBIO Inc. lost -₩4,500 in the last trading session, representing a -9.05% loss.

What is G2GBIO Inc. (456160) current market capitalization?

G2GBIO Inc. market cap is approximately 747.85 billion.

What is G2GBIO Inc. (456160) EBITDA?

G2GBIO Inc. EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -3.28 billion.

Does G2GBIO Inc. (456160) pay dividends?

No. G2GBIO Inc. does not pay a dividend.

What is G2GBIO Inc. (456160) beta (volatility) score?

G2GBIO Inc. has a beta of 0.187, indicating lower volatility than the overall market.